ClinicalTrials.gg
RecruitingNCT05885048FertiTOXUpdated Jul 30, 2026

Impact of Gonadotoxic Therapies on Fertility

An observational study in Cancer, Fertility Issues and Fertility Preservation, sponsored by Michael von Wolff. Recruiting at 1 site in Switzerland. Open to participants aged 14 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Michael von Wolff · Observational

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,000
Ages
14 Years to 50 Years
Sex
All
01

Study summary

The goal of this observational study is to learn how gonadotoxic treatments (chemotherapies, radiotherapies or immunotherapies) affect the fertility status of participants with cancer.

The main questions it aims to answer are:

  • in females, if cancer therapies reduce the Anti-Müllerian hormone (AMH) concentration (ovarian reserve);
  • in males, if cancer therapies reduce sperm concentration (sperm quality).
Read the detailed description

This is an international multicenter prospective exploratory study of fertility related data generated mostly routinely in fertility centers in Switzerland belonging to the Swiss network "FertiSAVE" as well as in fertility centers in Germany and Austria belonging to the German-Swiss-Austrian network "FertiPROTEKT" and further international centers who are interested to participate. Both networks include in total around 200 centers.

The data, which are mainly part of the routine clinical care, will be collected by the physicians and added to the REDcap study registry. Patients will be coded by the center to be able to follow them up. Each center will only have access to its own registry data set. Access to the total data set is only permitted for the principal investigator and the specific sub-investigators.

Data collection before the start of gonadotoxic treatment will be performed for 5 years.

Data collection after the end of gonadotoxic treatment will be performed for 10 years (time points: at 12-15 months, at 5 years and at 10 years).

02

Conditions studied

  • Cancer
  • Fertility Issues
  • Fertility Preservation
  • Toxicity Due to Chemotherapy
  • Toxicity Due to Radiotherapy
  • Effects of Immunotherapy

Keywords

  • Gonadotoxicity
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 7,000 is above the median of 200 across 2,641 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Michael von Wolff as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer participants from fertility centers (Switzerland, Germany and Austria)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with cancer or with benign reasons undergoing chemotherapy and/or radiotherapy of the pelvis (females) and the testicles (males) and/or immune therapy;
  • Willing to participate;
  • Austria: 14-50 years old (adolescents and adults), Germany: 18-50 years old, Switzerland: 14-50 years old (adolescents and adults);
  • Serum hormone analysis before gonadotoxic therapy (females) or serum hormone analysis and sperm analysis before gonadotoxic therapy (males).

Exclusion criteria

Exclusion Criteria:

  • Missing consent;
  • Language barrier.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Cancer female participants

    Fertility status before and after gonadotoxic treatment

    Diagnostic Test: Blood samples for analysis · Other: Satisfaction evaluation · Other: Quality of Life questionnaire

  • Cancer male participants

    Fertility status before and after gonadotoxic treatment

    Diagnostic Test: Blood samples for analysis · Diagnostic Test: Sperm samples for analysis · Other: Satisfaction evaluation · Other: Quality of Life questionnaire

Interventions

  • Diagnostic testBlood samples for analysis

    Test hormone levels in blood

  • Diagnostic testSperm samples for analysis

    Spermiogram

  • OtherSatisfaction evaluation

    Participant satisfaction assessment

  • OtherQuality of Life questionnaire

    The World Health Organization Quality of Life Brief 26-item Version (WHOQOL-BREF)

06

What researchers measure

Primary outcomes

  1. Anti-Müllerian hormone (AMH) concentration in females

    Fertility status after gonadotoxic treatment in females (referring to ovarian reserve). Blood will be drawn to measure AMH concentration. Unit of measure: for serum AMH value is picomol per liter (pmol/L).

    Time frame: Change from baseline in AMH concentration at 12-15 months after the end of gonadotoxic treatment

  2. Anti-Müllerian hormone (AMH) concentration in females

    Fertility status after gonadotoxic treatment in females (referring to ovarian reserve). Blood will be drawn to measure AMH concentration. Unit of measure: for serum AMH value is picomol per liter (pmol/L).

    Time frame: Change in AMH concentration at 5 years after time point 12-15 months after the end of gonadotoxic treatment

  3. Anti-Müllerian hormone (AMH) concentration in females

    Fertility status after gonadotoxic treatment in females (referring to ovarian reserve). Blood will be drawn to measure AMH concentration. Unit of measure: for serum AMH value is picomol per liter (pmol/L).

    Time frame: Change in AMH concentration at 10 years after time point 12-15 months after the end of gonadotoxic treatment

  4. Sperm concentration in males

    Fertility status after gonadotoxic treatment in males (referring to sperm quality). Participants provide the laboratory with a sperm sample for analysis. Unit of measure: for sperm concentration is millions per milliliter (10\^6/mL).

    Time frame: Change from baseline in sperm concentration at 12-15 months after the end of gonadotoxic treatment

  5. Sperm concentration in males

    Fertility status after gonadotoxic treatment in males (referring to sperm quality). Participants provide the laboratory with a sperm sample for analysis. Unit of measure: for sperm concentration is millions per milliliter (10\^6/mL).

    Time frame: Change in sperm concentration at 5 years after time point 12-15 months after the end of gonadotoxic treatment

  6. Sperm concentration in males

    Fertility status after gonadotoxic treatment in males (referring to sperm quality). Participants provide the laboratory with a sperm sample for analysis. Unit of measure: for sperm concentration is millions per milliliter (10\^6/mL).

    Time frame: Change in sperm concentration at 10 years after time point 12-15 months after the end of gonadotoxic treatment

Secondary outcomes

  1. Fertility preservation measures performed

    Proportion of female participants who freeze their ovarian tissue, oocytes, zygotes or embryos. Proportion of male participants who freeze their sperm or testicular tissue.

    Time frame: Before the start of gonadotoxic treatment

  2. Satisfaction with the fertility preservation counselling before the gonadotoxic treatment

    Both female and male participants will have to rate their counselling satisfaction by choosing a score on a scale from 1 to 10. Value 1, being the lowest score (not satisfied at all) and value 10 being the highest score (very satisfied).

    Time frame: 12-15 months after the end of gonadotoxic treatment

  3. Satisfaction with the decision to have undergone fertility preservation measures or not

    Both female and male participants will have to rate their decisional satisfaction by choosing a score on a scale from 1 to 10. Value 1, being the lowest score (not satisfied at all) and value 10 being the highest score (very satisfied).

    Time frame: 12-15 months after the end of gonadotoxic treatment

  4. Number of spontaneous pregnancies and children born

    Pregnancies which occured naturally, without the help of fertility preservation measures.

    Time frame: 12-15 months, 5 years and 10 years after the end of gonadotoxic treatment

  5. Number of pregnancies and children born with the help of fertility preservation measures

    Pregnancies which occured with the help of fertility preservation measures (in females: frozen ovarian tissue, oocytes, zygotes or embryos, and in males: frozen sperm or testicular tissue).

    Time frame: 12-15 months, 5 years and 10 years after the end of gonadotoxic treatment

  6. Quality of life assessment

    The World Health Organization Quality of Life Brief 26-item version (WHOQOL-BREF) is a 26-item instrument consisting of four domains: physical health (7 items), psychological health (6 items), social relationships (3 items), and environmental health (8 items), while the remaining two items are for the overall QoL and general health domains.

    Time frame: 12-15 months, 5 years and 10 years after the end of gonadotoxic treatment

07

Study locations

1 of 1 sites recruiting
  • University Women's Hospital (Inselspital)
    Bern, 3010, Switzerland
    Recruiting
08

References and documents

Publications

  • von Wolff M, Germeyer A, Bottcher B, Magaton IM, Marcu I, Pape J, Sanger N, Nordhoff V, Roumet M, Weidlinger S. Evaluation of the Gonadotoxicity of Cancer Therapies to Improve Counseling of Patients About Fertility and Fertility Preservation Measures: Protocol for a Retrospective Systematic Data Analysis and a Prospective Cohort Study. JMIR Res Protoc. 2024 Mar 20;13:e51145. doi: 10.2196/51145. PubMed 38506900 ↗
  • Weidlinger S, Graber S, Bratschi I, Pape J, Kollar A, Karrer T, von Wolff M. A Systematic Review of the Gonadotoxicity of Osteosarcoma and Ewing's Sarcoma Chemotherapies in Postpubertal Females and Males. J Adolesc Young Adult Oncol. 2024 Aug;13(4):597-606. doi: 10.1089/jayao.2023.0185. Epub 2024 Apr 17. PubMed 38629685 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2028, 60 months after the start.

Of 1,098 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 60 months is close to that.

Counting every sponsor, half of 1,246 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2023
First posted
Jun 1, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2038
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05885048
Lead sponsor
Michael von Wolff
Collaborators
University of Bern
Responsible party
Michael von Wolff (Prof. Dr. med. Michael von Wolff, Universitätsklinik fur Frauenheilkunde, Inselspital Bern) — Sponsor-investigator
First posted
Jun 1, 2023
Start date
Dec 1, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2038 (estimated)
Last update
Jul 30, 2026

Study contacts

Michael von Wolff, Prof. Dr.
Contact
michael.vonwolff@insel.ch
0041316321301
Michael von Wolff, Prof. Dr.
principal investigator · Insel Gruppe AG, University Hospital Bern

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion